Equities Analysts Offer Predictions for Pfizer Q1 Earnings

Pfizer Inc. (NYSE:PFE) – Analysts at Leerink Partnrs reduced their Q1 2025 earnings per share (EPS) estimates for Pfizer in a research report issued to clients and investors on Wednesday, February 5th. Leerink Partnrs analyst D. Risinger now forecasts that the biopharmaceutical company will post earnings of $0.54 per share for the quarter, down from their previous forecast of $0.58. The consensus estimate for Pfizer’s current full-year earnings is $2.96 per share. Leerink Partnrs also issued estimates for Pfizer’s Q4 2025 earnings at $0.80 EPS, FY2025 earnings at $2.99 EPS, FY2027 earnings at $3.01 EPS and FY2028 earnings at $2.63 EPS.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. The business had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The business’s quarterly revenue was up 24.7% on a year-over-year basis. During the same period in the prior year, the firm posted $0.10 earnings per share.

A number of other brokerages have also recently commented on PFE. Truist Financial lowered their price target on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. Sanford C. Bernstein started coverage on shares of Pfizer in a report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price objective for the company. Guggenheim lowered their target price on shares of Pfizer from $35.00 to $33.00 and set a “buy” rating on the stock in a research note on Wednesday, December 11th. StockNews.com lowered Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research report on Wednesday, October 23rd. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, Pfizer has an average rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Stock Up 2.3 %

PFE stock opened at $26.46 on Thursday. Pfizer has a 52 week low of $24.48 and a 52 week high of $31.54. The firm has a 50 day moving average of $26.27 and a 200 day moving average of $27.79. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The stock has a market capitalization of $149.94 billion, a PE ratio of 35.76, a price-to-earnings-growth ratio of 0.66 and a beta of 0.64.

Institutional Investors Weigh In On Pfizer

A number of large investors have recently modified their holdings of the business. Retirement Wealth Solutions LLC purchased a new stake in Pfizer in the 4th quarter valued at $26,000. Kohmann Bosshard Financial Services LLC acquired a new position in shares of Pfizer during the 4th quarter valued at about $28,000. Gladius Capital Management LP grew its holdings in shares of Pfizer by 102.8% in the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 38,015 shares during the period. Noble Wealth Management PBC acquired a new stake in Pfizer during the fourth quarter worth about $31,000. Finally, Sierra Ocean LLC purchased a new position in Pfizer during the fourth quarter worth about $34,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 dividend on an annualized basis and a yield of 6.50%. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio (DPR) is presently 232.44%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.